Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Down 22.7% in January

Dyadic International, Inc. (NASDAQ:DYAI) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 121,300 shares, a decline of 22.7% from the December 31st total of 157,000 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average daily volume of 91,200 shares, the short-interest ratio is presently 1.3 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Dyadic International in a research note on Thursday, November 14th.

Dyadic International Stock Performance

NASDAQ DYAI opened at $1.49 on Friday. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15. Dyadic International has a 1 year low of $0.93 and a 1 year high of $2.67. The company has a market capitalization of $44.09 million, a PE ratio of -6.48 and a beta of 0.89. The company has a fifty day moving average of $1.67 and a two-hundred day moving average of $1.39.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.06. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. The company had revenue of $1.96 million during the quarter, compared to the consensus estimate of $1.05 million. During the same quarter in the prior year, the firm posted ($0.06) earnings per share. As a group, analysts expect that Dyadic International will post -0.18 earnings per share for the current year.

Institutional Investors Weigh In On Dyadic International

A number of institutional investors and hedge funds have recently made changes to their positions in DYAI. Inlet Private Wealth LLC purchased a new stake in shares of Dyadic International in the fourth quarter valued at about $52,000. Truist Financial Corp purchased a new stake in shares of Dyadic International in the fourth quarter valued at about $428,000. Finally, Chapin Davis Inc. raised its holdings in shares of Dyadic International by 2.5% in the third quarter. Chapin Davis Inc. now owns 868,301 shares of the biotechnology company’s stock valued at $903,000 after buying an additional 21,000 shares during the last quarter. 27.95% of the stock is owned by hedge funds and other institutional investors.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.